These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15717887)

  • 1. Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.
    Kouki T; Takasu N; Nakachi A; Tamanaha T; Komiya I; Tawata M
    Diabet Med; 2005 Mar; 22(3):346-7. PubMed ID: 15717887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
    Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy.
    Abe H; Mita T; Kudo K; Funayama T; Tokoro M; Kaga H; Ikeda F; Kanazawa A; Hirose T; Kawamori R; Watada H
    Endocr J; 2009; 56(7):911-3. PubMed ID: 19506327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
    Yamanouchi T; Sakai T; Igarashi K; Ichiyanagi K; Watanabe H; Kawasaki T
    Diabet Med; 2005 Aug; 22(8):980-5. PubMed ID: 16026361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.
    Derosa G; Franzetti I; Gadaleta G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Jun; 17(3):143-50. PubMed ID: 15334791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
    Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag A
    Diabetes Obes Metab; 2007 May; 9(3):394-407. PubMed ID: 17391168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
    Kabadi UM; Kabadi M
    Diabetes Res Clin Pract; 2006 Jun; 72(3):265-70. PubMed ID: 16406190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
    Poulsen MK; Henriksen JE; Hother-Nielsen O; Beck-Nielsen H
    Diabetes Care; 2003 Dec; 26(12):3273-9. PubMed ID: 14633813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.
    Cook MN; Girman CJ; Stein PP; Alexander CM
    Diabet Med; 2007 Apr; 24(4):350-8. PubMed ID: 17335466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Gallwitz B; Guzman J; Dotta F; Guerci B; Simó R; Basson BR; Festa A; Kiljański J; Sapin H; Trautmann M; Schernthaner G
    Lancet; 2012 Jun; 379(9833):2270-8. PubMed ID: 22683137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.